A new study from SAHMRI and the University of Adelaide has found the number of children being born with cerebral palsy (CP) each year across Australia and New Zealand could be cut by more than 20, if hospitals improve their practices around giving women magnesium sulfate just before they have a very preterm baby.
by South Australian Health and Medical Research Institute (SAHMRI) via Medical Xpress, November 20, 2021
Magnesium sulfate delivered via intravenous infusion to women giving birth at less than 30 weeks gestation is well proven to significantly reduce the risk of children being born with CP.
Associate Professor Amy Keir, who led the study to improve its use, says the healthcare system isn’t always well set up to get magnesium sulfate to the women that need it.
“Administering magnesium sulfate to women giving birth very preterm is now standard practice, but unfortunately, that doesn’t mean it’s being delivered in every case,” A/Prof Keir said.
“Our research shows how costly it is when we don’t get this right. We found that there are almost one million dollars in lifetime healthcare costs for every child with CP. Not to mention, the pain and discomfort for the child with CP, who will require these hospitalisations and care throughout their life.”
By implementing a quality improvement (QI) program at one hospital in Adelaide, A/Prof Keir says the team was able to boost its magnesium sulfate coverage from 63% to 86% of eligible women, resulting in a projected five fewer children with CP over five years.
The program included a dedicated clinician-led QI team consisting of a neonatologist, midwife, and neonatal nurse trained in QI methodology. The team addressed the barriers to magnesium sulfate administration with changes such as making magnesium sulfate available in multiple locations throughout the hospital instead of just one area.
“Even though clinicians know what needs to be done when it comes to dispensing these drugs, the process is often complicated, and in the rush of a stressful potential premature birth in the hospital environment, it can result in some women not receiving what they need, when they need it,” A/Prof Keir said.
There are many other hospitals where babies are born very preterm throughout Australia and New Zealand and A/Prof Keir says she’s confident each unit could achieve a similar increase in efficiency through implementing a QI program.
But these programs cost time and money and need to be prioritized.
A/Prof Keir says funding for undertaking such improvement work and sustaining its impact, is not always readily available.
“If other units across Australia and New Zealand were supported to do similar work, they too would be able to prevent a significant number of children developing CP,” A/Prof Keir said.
It’s hoped the study results will highlight the importance of appropriately resourcing the implementation of evidence-based practice guidelines into prenatal care.
Source Medical Xpress via South Australian Health and Medical Research Institute (SAHMRI)
Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program, Keir A, Rumbold A, Shepherd E, Mcintyre S, Groves C, Cavallaro A, Crowther C, Callander E. Aust N Z J Obstet Gynaecol. 2021 Nov 29. doi: 10.1111/ajo.13459. Epub ahead of print.
Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis, Shepherd E, Salam RA, Manhas D, Synnes A, Middleton P, Makrides M, Crowther CA. PLoS Med. 2019 Dec 6;16(12):e1002988. doi: 10.1371/journal.pmed.1002988. Full text
Protection of brain development by antenatal magnesium sulphate for infants born preterm, Chollat C, Sentilhes L, Marret S. Dev Med Child Neurol. 2019 Jan;61(1):25-30. doi: 10.1111/dmcn.14038. Epub 2018 Oct 7. Full text
Optimization of Maternal Magnesium Sulfate Administration for Fetal Neuroprotection: Application of a Prospectively Constructed Pharmacokinetic Model to the BEAM Cohort, Brookfield KF, Elkomy M, Su F, Drover DR, Carvalho B. J Clin Pharmacol. 2017 Nov;57(11):1419-1424. doi: 10.1002/jcph.941. Epub 2017 Jun 6.
Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection, Burhouse A, Lea C, Ray S, Bailey H, Davies R, Harding H, Howard R, Jordan S, Menzies N, White S, Phillips K, Luyt K. BMJ Open Qual. 2017 Oct 12;6(2):e000189. doi: 10.1136/bmjoq-2017-000189. Full text
Antenatal magnesium sulphate administration for fetal neuroprotection: a French national survey, Chollat C, Le Doussal L, de la Villéon G, Provost D, Marret S. BMC Pregnancy Childbirth. 2017 Sep 13;17(1):304. doi: 10.1186/s12884-017-1489-z. Full text
The Evidence-based Practice for Improving Quality method has greater impact on improvement of outcomes than dissemination of practice change guidelines and quality improvement training in neonatal intensive care units, Lee SK, Aziz K, Singhal N, Cronin CM. Paediatr Child Health. 2015 Jan-Feb;20(1):e1-9. Full text
Association of a quality improvement program with neonatal outcomes in extremely preterm infants: a prospective cohort study, Lee SK, Shah PS, Singhal N, Aziz K, Synnes A, McMillan D, Seshia MM; Canadian EPIQ Study Group. CMAJ. 2014 Sep 16;186(13):E485-94. doi: 10.1503/cmaj.140399. Epub 2014 Aug 18. Full textcp128_mag_sulphate_child
Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Prepared by the Antenatal Magnesium Sulphate For Neuroprotection Guideline Development Panel. Australian Research Centre for Health of Women and Babies, The University of Adelaide 2010
Study reveals level of magnesium sulfate to prevent cerebral palsy in preterm infants Medical Xpress